Related Experiment Video
Updated: Mar 20, 2026
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Forecasting Cytokine Storms with New Predictive Biomarkers.
Rayne H Rouce1, Helen E Heslop2
1Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital, Houston, Texas. Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, Texas.
Researchers identified biomarkers to predict cytokine release syndrome (CRS), a complication of CD19 chimeric antigen receptor (CAR) T-cell therapy for B-cell malignancies. This may enable earlier interventions to manage CRS without compromising treatment efficacy.
Area of Science:
- Immunotherapy
- Oncology
- Biomarker Discovery
Background:
- CD19 chimeric antigen receptor (CAR) T-cell therapy shows promise for B-cell malignancies.
- Cytokine release syndrome (CRS) is a significant, potentially fatal complication of CAR T-cell therapy.
Purpose of the Study:
- To identify predictive biomarkers for CRS following CD19 CAR T-cell therapy.
- To explore early intervention strategies for CRS management.
Main Methods:
- Analysis of patient data to identify factors predicting CRS development.
- Evaluation of potential therapeutic agents, such as IL6 receptor blockers (e.g., tocilizumab).
Main Results:
- Identification of predictive biomarkers for CRS.
- Potential for earlier intervention to mitigate CRS severity.
Conclusions:
- Predictive biomarkers can facilitate timely interventions for CRS.
- Managing CRS with agents like tocilizumab may improve patient outcomes without hindering CAR T-cell efficacy.
